目的 探讨炎性乳腺癌的临床特点和治疗方法。 方法 对我院1989年2月至1997年11月期间诊治的17例炎性乳腺癌患者的临床资料进行回顾性分析。 结果 17例患者中8例行新辅助化疗+乳腺癌改良根治术+术后放疗及化疗患者的平均生存期为33.6个月，1、2、5年仍存活者分别为6例、5例和3例，行其他治疗的9例患者1、2、5年仍存活者分别为5例、3例和0例。 结论 新辅助化疗+乳腺癌改良根治术+术后放疗及化疗可提高患者生存率。
ObjectiveTo investigate the prognostic factors for inflammatory breast cancer based on the data from West China Hospital with a relatively large sample. MethodsClinical data of 41 patients with histopathologically confirmed inflammatory breast cancer (IBC) who received treatment at West China Hospital Oncology Center of Sichuan University between January 2009 and December 2014 were collected and analyzed. Log-rank test and Cox regression model were used for statistical analysis. ResultsIn the study, negative estrogen receptor, negative progestrone receptor and positive human epidermal growth factor receptor-2 were identified in 58.5%, 61.0% and 34.2% of the inflammatory breast cancer tissues, respectively. Progress free survival (PFS) were between 2 and 60 months, with a median of 35 months. Univariate analysis showed that Tumor Node Metastasis (TNM) stage (P=0.016) and therapeutic effect (P=0.002) influenced the survival. Multivariate analysis showed that TNM stage (P=0.006), therapeutic effect (P=0.002), and anthracycline-taxane based chemotherapy (P=0.041) were the significant prognostic factors. ConclusionTNM stage is the major prognostic factor for IBC. Preoperative chemotherapy with paclitaxel-epirubicin combination can improve the PFS of IBC. Comprehensive treatment mode with operation is recommended for the treatment of IBC.